AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27942720 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 549
Study 26505870 — intervention group
Group type: EXPERIMENTAL
Intervention: ESCAPE‐DD curriculum
Number of subjects: 58
Study 26505870 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 58
Study 24491463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (MgSO4 50mg/kg in 100 mL of normal saline over 15 min before anesthesia induction, followed by an infusion of 15 mg/kg/hour)
Number of subjects: 50
Study 24491463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 50
Study 24491463 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 50
Study 21689089 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP level ≥160ng/l
Number of subjects: 758
Study 18471448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation training program (3 months, exercise intensity 55% to 70% of peak VO2)
Number of subjects: 39
Study 18471448 — intervention group
Group type: COMPARATOR
Intervention: Nontraining group (usual lifestyle)
Number of subjects: 39
Study 16503677 — intervention group
Group type: EXPERIMENTAL
Intervention: High-CHO diet (6.5 g CHO kg body mass(‐1))
Number of subjects: 8
Study 16503677 — intervention group
Group type: COMPARATOR
Intervention: Moderate-CHO diet (4.4 g CHO kg body mass(‐1))
Number of subjects: 8
Study 16503677 — intervention group
Group type: EXPERIMENTAL
Intervention: High-CHO diet
Number of subjects: 8
Study 16503677 — intervention group
Group type: COMPARATOR
Intervention: Moderate-CHO diet
Number of subjects: 8
Study 12757968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment group
Number of subjects: 76
Study 12757968 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual group
Number of subjects: 76
Study 10974381 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (XRT)
Number of subjects: 99
Study 10974381 — intervention group
Group type: COMPARATOR
Intervention: Endobronchial brachytherapy (EBT)
Number of subjects: 99
Study 10974381 — intervention group
Group type: COMPARATOR
Intervention: Clinician assessments
Number of subjects: 99
Study 9194044 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 9194044 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants
Number of subjects: 0
Study 9194044 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated patients
Number of subjects: 0
Study 8118749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (APD)
Number of subjects: 22
Study 8118749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8118749 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 (100 micrograms/day)
Number of subjects: 22
Study 3136210 — intervention group
Group type: EXPERIMENTAL
Intervention: J5-IVIG
Number of subjects: 100
Study 3136210 — intervention group
Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 100
Study 30900008 — intervention group
Group type: EXPERIMENTAL
Intervention: Phendimetrazine 210 mg
Number of subjects: 29
Study 30900008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 30900008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (0, 20, 40, and 80 mg intranasal)
Number of subjects: 29
Study 30900008 — intervention group
Group type: EXPERIMENTAL
Intervention: Phendimetrazine
Number of subjects: 29
Study 28468840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment
Number of subjects: 760
Study 26619143 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic Community Engagement (SCE) interventions in intervention facilities
Number of subjects: 64
Study 26619143 — intervention group
Group type: COMPARATOR
Intervention: Control facilities (no SCE intervention)
Number of subjects: 64
Study 23314228 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator sling surgery
Number of subjects: 100
Study 23314228 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control)
Number of subjects: 100
Study 21262413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - three manualized sessions including one physical activity exposure session
Number of subjects: 40
Study 21262413 — intervention group
Group type: COMPARATOR
Intervention: Usual care from general practitioner
Number of subjects: 40
Study 18655472 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.6 g protein/kg/day) balanced by high-calorie mix containing protein SUPRO 760 or ketosteril for 24-48 months
Number of subjects: 200
Study 17217711 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 351
Study 17217711 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 351
Study 17217711 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg and Irbesartan 150 mg
Number of subjects: 351
Study 12662006 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine
Number of subjects: 120
Study 12662006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 11147940 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiband ligation
Number of subjects: 45
Study 11147940 — intervention group
Group type: COMPARATOR
Intervention: Conventional ligation
Number of subjects: 45
Study 9378192 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic guidance during endomyocardial biopsy (EMB)
Number of subjects: 38
Study 9378192 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopic guidance during endomyocardial biopsy (EMB)
Number of subjects: 38
Study 8097114 — intervention group
Group type: EXPERIMENTAL
Intervention: Raclopride 2 mg
Number of subjects: 17
Study 8097114 — intervention group
Group type: EXPERIMENTAL
Intervention: Raclopride 6 mg
Number of subjects: 17
Study 8097114 — intervention group
Group type: EXPERIMENTAL
Intervention: Raclopride 12 mg
Number of subjects: 17
Study 8097114 — intervention group
Group type: EXPERIMENTAL
Intervention: Raclopride (all doses)
Number of subjects: 17
Study 2880747 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (plasma concentration 25-45 mumol/l)
Number of subjects: 20
Study 2880747 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (plasma concentration 50-85 mumol/l)
Number of subjects: 20
Study 2880747 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mumol/l)
Number of subjects: 20
Study 2880747 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (various concentrations)
Number of subjects: 20
Study 31599019 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine
Number of subjects: 208
Study 31599019 — intervention group
Group type: COMPARATOR
Intervention: usual intake (control)
Number of subjects: 208
Study 29473237 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Dads Healthy Kids (HDHK) intervention
Number of subjects: 93
Study 26876690 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI-FES
Number of subjects: 20
Study 26876690 — intervention group
Group type: COMPARATOR
Intervention: FES
Number of subjects: 20
Study 26876690 — intervention group
Group type: COMPARATOR
Intervention: BCI-FES vs FES
Number of subjects: 20
Study 25639126 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education promoting consumption of khichuri
Number of subjects: 300
Study 25639126 — intervention group
Group type: COMPARATOR
Intervention: Routine services from health facilities
Number of subjects: 300
Study 23896317 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (HF) rTMS treatment
Number of subjects: 20
Study 23896317 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 20
Study 20131046 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical parallel arrays of short line segments
Number of subjects: 6
Study 20131046 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal parallel arrays of short line segments
Number of subjects: 6
Study 20131046 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric arrays of short line segments
Number of subjects: 6
Study 20131046 — intervention group
Group type: COMPARATOR
Intervention: Randomly oriented segments
Number of subjects: 6
Study 19037765 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual pad with emollient-treated surface layer and polymeric absorbent foam core
Number of subjects: 0
Study 19037765 — intervention group
Group type: COMPARATOR
Intervention: Conventional marketed pads
Number of subjects: 0
Study 16176526 — intervention group
Group type: EXPERIMENTAL
Intervention: J-shaped leads (JL)
Number of subjects: 208
Study 16176526 — intervention group
Group type: COMPARATOR
Intervention: Straight leads (SL)
Number of subjects: 208
Study 16176526 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (JL and SL)
Number of subjects: 208
Study 12509549 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape intervention (videotape, PCC pamphlet, and PCC stickers)
Number of subjects: 289
Study 12509549 — intervention group
Group type: COMPARATOR
Intervention: Regularly scheduled WIC class (control group)
Number of subjects: 289
Study 10442725 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon expander (SE)
Number of subjects: 16
Study 10442725 — intervention group
Group type: EXPERIMENTAL
Intervention: Translational recession (TR)
Number of subjects: 16
Study 8692630 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH (0.2 IU/kg/day subcutaneously to a maximum of 16 IU/day) for 7 days
Number of subjects: 20
Study 8692630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1775263 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis with desferrioxamine (1 g intravenously 24‐40 h before dialysis); n = 28
Number of subjects: 64
Study 1775263 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemofiltration with desferrioxamine (1 g intravenously 24‐40 h before haemofiltration); n = 36
Number of subjects: 64
Study 6675065 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% prilocaine (4 mg/kg body weight)
Number of subjects: 20
Study 6675065 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% prilocaine (4 mg/kg body weight)
Number of subjects: 20
Study 6675065 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% prilocaine (4 mg/kg body weight)
Number of subjects: 20
Study 6675065 — intervention group
Group type: COMPARATOR
Intervention: 0.8% prilocaine
Number of subjects: 20
Study 6675065 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% prilocaine
Number of subjects: 20
Study 31809905 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg zopiclone
Number of subjects: 16
Study 31809905 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg zopiclone
Number of subjects: 16
Study 31809905 — intervention group
Group type: COMPARATOR
Intervention: Both dosing groups
Number of subjects: 16
Study 31809905 — intervention group
Group type: EXPERIMENTAL
Intervention: N-desmethylzopiclone
Number of subjects: 16
Study 31809905 — intervention group
Group type: EXPERIMENTAL
Intervention: zopiclone N-oxide
Number of subjects: 16
Study 31809905 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mm hair segments
Number of subjects: 16
Study 31809905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling 1-2 months after exposure
Number of subjects: 16
Study 31277533 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing brace after small splint external fixation
Number of subjects: 60
Study 31277533 — intervention group
Group type: COMPARATOR
Intervention: Control group with small splint external fixation
Number of subjects: 60
Study 28527873 — intervention group
Group type: EXPERIMENTAL
Intervention: LED light handle
Number of subjects: 42
Study 28527873 — intervention group
Group type: COMPARATOR
Intervention: Xenon halogen
Number of subjects: 42
Study 27274152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental health education by trained schoolteachers at intervals of 15 days, 1 month, and 3 months
Number of subjects: 71
Study 27274152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental health education by dental professionals at intervals of 15 days, 1 month, and 3 months
Number of subjects: 71
Study 27274152 — intervention group
Group type: COMPARATOR
Intervention: No further dental health education (control group)
Number of subjects: 71
Study 25057211 — intervention group
Group type: COMPARATOR
Intervention: fMRI investigation of the extrastriate body area (EBA) in blind and sighted subjects
Number of subjects: 0
Study 25057211 — intervention group
Group type: COMPARATOR
Intervention: Sensitivity of the superior part of the EBA and supramarginal gyrus
Number of subjects: 0
Study 25057211 — intervention group
Group type: COMPARATOR
Intervention: Sensitivity of the inferior part of the EBA
Number of subjects: 0
Study 21365326 — intervention group
Group type: EXPERIMENTAL
Intervention: A2A2 genotype of the PIN3 (+16 bp) polymorphism in patients treated with chemotherapy without anthracycline
Number of subjects: 94
Study 21365326 — intervention group
Group type: COMPARATOR
Intervention: TP53 polymorphisms, Arg72Pro and PIN3 (+16 bp)
Number of subjects: 94
Study 21365326 — intervention group
Group type: COMPARATOR
Intervention: TNM stage
Number of subjects: 94
Study 21365326 — intervention group
Group type: COMPARATOR
Intervention: Grade
Number of subjects: 94
Study 20675336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 169
Study 20675336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin + Vancomycin
Number of subjects: 169
Study 20675336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin + Daptomycin
Number of subjects: 169
Study 17404368 — intervention group
Group type: COMPARATOR
Intervention: High-dose chemotherapy (HDC) with autologous hematopoietic progenitor cell support (AHPCS)
Number of subjects: 536
Study 17404368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense and dose-escalated chemotherapy with doxorubicin, paclitaxel, and cyclophosphamide
Number of subjects: 536
Study 15827104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alendronate (ALN) at a dose of 125 mcg
Number of subjects: 24
Study 15827104 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alendronate (ALN) 35 mg for patients weighing less than 40 kg
Number of subjects: 24
Study 15827104 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alendronate (ALN) 70 mg for patients weighing 40 kg or more
Number of subjects: 24
Study 15827104 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse experiences from single-dose ALN
Number of subjects: 24
Study 15827104 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory safety monitoring
Number of subjects: 24
Study 12905641 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/d
Number of subjects: 56
Study 12905641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 9877516 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral salt (MS) group
Number of subjects: 21
Study 9877516 — intervention group
Group type: COMPARATOR
Intervention: Regular salt (RS) group
Number of subjects: 21
Study 8934956 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0
Study 8934956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2529370 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at 1.2 pmol kg‐1 min‐1
Number of subjects: 8
Study 2529370 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down tilt
Number of subjects: 8
Study 2529370 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8
Study 385398 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg daily
Number of subjects: 35
Study 385398 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 1200 mg daily
Number of subjects: 35
Study 31843633 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainless group (n=50)
Number of subjects: 100
Study 31843633 — intervention group
Group type: COMPARATOR
Intervention: Drainage group (n=50)
Number of subjects: 100
Study 31813281 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 178
Study 31813281 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 178
Study 26853191 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 60
Study 26853191 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 60
Study 26575256 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1200 mg/day
Number of subjects: 547
Study 26575256 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800 mg/day
Number of subjects: 547
Study 26575256 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ESL arms (800 and 1200 mg/day)
Number of subjects: 547
Study 26575256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study 23021320 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS (N=155)
Number of subjects: 301
Study 23021320 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS (N=146)
Number of subjects: 301
Study 20736382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Pro‐Self(©) exercise during and after chemotherapy
Number of subjects: 100
Study 20736382 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no Pro‐Self)
Number of subjects: 100
Study 19359920 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bupivacaine infusion through thoracic epidural (TEA)
Number of subjects: 30
Study 19359920 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bupivacaine infusion through thoracic paravertebral block (TPVB)
Number of subjects: 30
Study 19359920 — intervention group
Group type: COMPARATOR
Intervention: TEA
Number of subjects: 30
Study 19359920 — intervention group
Group type: COMPARATOR
Intervention: TPVB
Number of subjects: 30
Study 16309809 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg of E. amoenum aqueous extract
Number of subjects: 35
Study 16309809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 15564180 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) alone
Number of subjects: 1012
Study 15564180 — intervention group
Group type: COMPARATOR
Intervention: Axillary clearance (AC) plus SLNB
Number of subjects: 1012
Study 11741108 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral single-dose (20 mg) ketanserin
Number of subjects: 31
Study 11741108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9212953 — intervention group
Group type: EXPERIMENTAL
Intervention: HPM‐15 (Nikkiso Co.)
Number of subjects: 4
Study 9212953 — intervention group
Group type: EXPERIMENTAL
Intervention: Capiox (Terumo Co.)
Number of subjects: 4
Study 9212953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestream (St. Jude Medical Co.)
Number of subjects: 4
Study 9212953 — intervention group
Group type: EXPERIMENTAL
Intervention: BP‐80 (Medtronic, BioMedicus Co.)
Number of subjects: 4
Study 8219660 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (9 g daily for 6 weeks)
Number of subjects: 10
Study 8219660 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (9 g daily for 6 weeks)
Number of subjects: 10
Study 2887475 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) + cimetidine
Number of subjects: 0
Study 2887475 — intervention group
Group type: COMPARATOR
Intervention: Colloidal bismuth subcitrate (CBS) alone
Number of subjects: 0
Study 2887475 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine alone
Number of subjects: 0
Study 29283450 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting samples
Number of subjects: 4177
Study 29283450 — intervention group
Group type: COMPARATOR
Intervention: Non-fasting samples
Number of subjects: 4177
Study 26271931 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RET) for 8 weeks
Number of subjects: 21
Study 24980467 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐CRM vaccine (two‐ or three‐dose primary infant series plus a single toddler dose)
Number of subjects: 0
Study 24980467 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐CRM vaccine (three‐dose infant primary series)
Number of subjects: 0
Study 24980467 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐CRM vaccine (two‐dose toddler catch‐up series)
Number of subjects: 0
Study 24980467 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐CRM vaccine with concomitant routine vaccines
Number of subjects: 0
Study 24980467 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐CRM vaccine (three‐dose infant series)
Number of subjects: 0
Study 22234287 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed power training (40% to 75% of 1RM); 3 sets of 4-12 reps, countermovement jump, and 1.5 kg medicine ball throwing
Number of subjects: 56
Study 22234287 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 56
Study 20369277 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intervention (EI)
Number of subjects: 0
Study 20369277 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intervention with Work Transition (EI/WT)
Number of subjects: 0
Study 20369277 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 0
Study 19192856 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) during standard care
Number of subjects: 75
Study 19192856 — intervention group
Group type: COMPARATOR
Intervention: Standard care without CM
Number of subjects: 75
Study 16996947 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (150 mg/kg daily; 300 mg/kg on the day of surgery, then orally 12 g/day up to 6 weeks after surgery)
Number of subjects: 98
Study 16996947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 16996947 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 98
Study 12974696 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Caine Peel (30-minute application)
Number of subjects: 20
Study 12974696 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (30-minute application)
Number of subjects: 20
Study 11004038 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (propofol-nitrous oxide with laryngeal mask airway, anesthetic depth titrated to bispectral index level of 40-60)
Number of subjects: 48